We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Punicalagin Alleviates Psoriasis by Inhibiting NF-κB-Mediated IL-1β Transcription and Caspase-1-Regulated IL-1β Secretion.
- Authors
Tang, Lipeng; Li, Tong; Zhang, Bowen; Zhang, Zihao; Sun, Xiaoyi; Zhu, Ying; Feng, Bing; Su, Zuqing; Yang, Laijun; Li, Hongxia; Liu, Huazhen; Chen, Yuchao; Dai, Zhenhua; Zheng, Xirun; Li, Mingxian; Li, Chutian; Zhao, Jie; Qiu, Xinmin; Ye, Shuyan; Liu, Han
- Abstract
Psoriasis is a chronic and inflammatory skin disorder characterized by inflammation and epidermal hyperplasia. Punicalagin (PUN) is a main active ingredient of pomegranate (Punica granatum L.) peel with multiple biological activities, such as antibacterial, antioxidant and anti-tumor effects. However, the potential effect of PUN on psoriasis remains unknown. In this study, we want to investigate the pharmacological effect of PUN on psoriasis by using imiquimod (IMQ)-induced psoriatic mice model in vivo and tumor necrosis factor a (TNF-α) and interleukin-17A (IL-17A)-stimulated HaCaT cells in vitro. Our results showed that PUN can effectively alleviate the severity of psoriasis-like symptoms. Mechanistically, PUN potently suppresses the aberrant upregulation of interleukin-1β (IL-1β) and subsequent IL-1β-mediated inflammatory cascade in keratinocytes by inhibiting the nuclear factor kappa B (NF-κB) activation and cleaved caspase-1 expression in vitro and in vivo. Taken together, our findings indicate that PUN can relieve psoriasis by repressing NF-κB-mediated IL-1β transcription and caspase-1-regulated IL-1β secretion, which provide evidence that PUN might represent a novel and promising candidate for the treatment of psoriasis.
- Subjects
NF-kappa B; TUMOR necrosis factors; PSORIASIS; POMEGRANATE
- Publication
Frontiers in Pharmacology, 2022, Vol 13, p1
- ISSN
1663-9812
- Publication type
Article
- DOI
10.3389/fphar.2022.817526